Pfizer Sues Ranbaxy, Teva Over Accupril Patent
The lawsuit, filed in late January in the U.S. District Court for the District of New Jersey, alleges that Ranbaxy infringes a process patent held by Parke-Davis, which was later acquired by Pfizer.
Ranbaxy's generic version reaches the U.S. market under Teva’s label through a supply agreement between the two companies.
Teva was granted six-month marketing...
To view the full article, register now.